Related Experiment Video
Updated: Jun 24, 2026
07:50
Assay Development for High-Throughput Drug Screening Against Mycobacteria
Published on: October 25, 2024
Iron trafficking as an antimicrobial target
Rosanne E Frederick1, Jeffery A Mayfield, Jennifer L DuBois
1Department of Chemistry and Biochemistry, University of Notre Dame, IN 46556, USA.
Summary
Microbial iron uptake pathways are crucial for pathogen survival and offer targets for new antimicrobial strategies. This review highlights medicinal inhibition of these essential microbial iron acquisition mechanisms.
Area of Science:
- Microbiology
- Biochemistry
- Antimicrobial drug discovery
Background:
- Iron is an essential element for the survival of most organisms, including pathogens.
- Microbial iron acquisition pathways are complex and differ significantly from those in higher eukaryotes.
- Targeting microbial iron acquisition presents a promising strategy for developing novel antimicrobial therapies.
Purpose of the Study:
- To provide a concise overview of general microbial iron uptake pathways.
- To summarize current research on the medicinal inhibition of these pathways.
- To explore the potential of targeting microbial iron acquisition as an antimicrobial strategy.
Main Methods:
- Literature review of microbial iron acquisition mechanisms.
- Summary of existing and emerging medicinal inhibitors of iron uptake pathways.
- Analysis of the therapeutic potential of targeting microbial iron metabolism.
Main Results:
- Microbial iron acquisition involves diverse and complex mechanisms.
- Several strategies are being investigated to inhibit these pathways, offering potential antimicrobial effects.
- Inhibition of iron uptake can selectively target pathogenic microbes.
Conclusions:
- Targeting microbial iron acquisition pathways is a viable antimicrobial strategy.
- Further research into medicinal inhibition of these pathways could lead to new treatments for infectious diseases.
- Understanding microbial iron metabolism is key to developing effective antimicrobial interventions.
Related Concept Videos
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:23Antimicrobial Proteins
Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:25Inhibitors of Bacterial Protein Synthesis
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...